Abstract

Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a complex interplay between T cells, dendritic cells and the epidermis in which T cells and dendritic cells maintain skin inflammation. Anti-tumour necrosis factor (anti-TNF-α) agents have been approved for therapeutic use across a range of inflammatory disorders including psoriasis, but the anti-inflammatory mechanisms of anti-TNF-α in lesional psoriatic skin are not fully understood. We investigated early events in skin from psoriasis patients after treatment with anti-TNF-α antibodies by use of bioinformatics tools. We used the Human Gene 1.0 ST Array to analyse gene expression in punch biopsies taken from psoriatic patients before and also 4 and 14 days after initiation of treatment with the anti-TNF-α agent adalimumab. The gene expression was analysed by gene set enrichment analysis using the Functional Annotation Tool from DAVID Bioinformatics Resources. The most enriched pathway was visualised by the Pathview Package on Kyoto Encyclopedia of Genes and Genomes (KEGG) graphs. The analysis revealed new very early events in psoriasis after adalimumab treatment. Some of these events have been described after longer periods of anti-TNF-α treatment when clinical and histological changes appear, suggesting that effects of anti-TNF-α treatment on gene expression appear very early before clinical and histological changes. Combining microarray data on biopsies from psoriasis patients with pathway analysis allowed us to integrate in vitro findings into the identification of mechanisms that may be important in vivo. Furthermore, these results may reflect primary effect of anti-TNF-α treatment in contrast to studies of gene expression changes following clinical and histological changes, which may reflect secondary changes correlated to the healing of the skin.
Introduction

The skin harbors multiple systems that, e.g., encompasses the skin immune system in order to protect the body and maintain local homeostasis [1–3]. Psoriasis is a chronic cutaneous inflammatory disease affecting 2–3% of the population [4]. Its immunopathogenesis has been described as a cross-talk between T cells, dendritic cells (DCs) and the epidermis [5, 6]. A complex interplay generates the inflammatory process, and it was previously described that T cells and DCs maintain skin inflammation [7]. Studies of skin samples from patients treated with anti-tumour necrosis factor (anti-TNF-α) agents have confirmed that DCs and T cells play a role in the pathogenesis of psoriasis, and anti-TNF-α has been shown to regulate both Th17 responses and IL-23 and Th17 cytokine expression in lesional psoriatic skin [8, 9]. Many gene expression studies of the in vivo effect of anti-TNF-α have been conducted two weeks or later after treatment start where the histological and clinical changes start appearing. Findings at these time points reveal genes that may be important in the pathogenesis of psoriasis as well as direct or indirect targets of anti-TNF-α agents [10, 11].

Anti-TNF-α agents have been approved for therapeutic use across a range of inflammatory disorders, including Crohn’s disease, rheumatoid arthritis, spondyloarthropathy and psoriasis [12–16]. Despite the fact that >500,000 patients worldwide have been treated with anti-TNF-α drugs like infliximab, adalimumab and etanercept, the anti-inflammatory mechanisms of these agents in lesional psoriatic skin are not fully understood [8]. TNF-α achieves its effect through a complicated interplay of both cell differentiation and expression of inflammatory genes [17, 18]. In vitro models may not be able to fully explain the mode of action of TNF-α in gene regulation in inflammatory diseases, and in vivo studies therefore still seem warranted [8].

Inhibition of TNF-α is known to modulate a wide panel of genes involved in immune and inflammatory responses. Some of these genes, including IL-8, IL-1β, CXCL10, and CXCL11 represent direct targets of TNF-α [19–21], whereas others are the result of an indirect effect that reflects changes in the cell and cytokine network occurring within the target tissues [8–10, 22, 23].

High-throughput technologies like gene expression arrays provide a fundamental starting point in the identification of mechanistic causes and regulatory signalling pathways. One standard method involves identifying differentially expressed genes (DEGs). However, this method offers only limited information regarding the biological function of the differentially expressed genes. Another method is gene set enrichment analysis (GSEA) which uses pathway knowledge to detect biologically relevant signals; e.g. the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched by a set of genes can be identified and visualised and this approach provides a better understanding of relevant DEGs in a given context.

In the present study, we analysed punch biopsies from psoriatic patients before treatment and after adalimumab treatment; untreated nonlesional skin (NL), untreated lesional skin (L0), lesional skin 4 days after treatment start (L4) and lesional skin 14 days after treatment start (L14). We used the Human Gene 1.0 ST Array and the gene expression was analysed by GSEA using the Functional Annotation Tool from DAVID Bioinformatics Resources [24, 25]. The most enriched pathway was visualised using the Pathview Package on KEGG graphs [26].

Materials and Methods

Patient material

The patients included were adults (> 18 years) with psoriasis vulgaris who were going to be treated with anti-TNF-α drugs independently of the project. Patients were excluded if they had received local treatment two weeks before inclusion or had received any systemic treatment.
including UVB 6 weeks prior to the inclusion date or five half-lives of the drug, whichever was longest. At inclusion patients started treatment with adalimumab 80 mg at week 0, 40 mg at week 1 followed by 40 mg every other week. Treatment was started according to local guidelines and independent of this protocol. Before and during treatment, patients were monitored clinically with a Psoriasis Area Severity Index (PASI) score. Clinical evaluation was conducted by a trained dermatologist at the session at which punch biopsies were also taken. The study was approved by the regional ethical committee of Region Midtjylland (approval no. m-20090102) and performed according to the principles of the Declaration of Helsinki. Signed informed consent was obtained from each patient. 4 mm punch biopsies from lesional and nonlesional psoriatic skin were obtained from 10 psoriatic patients using a local anaesthetic containing 1% lidocaine at day 0 (NL and L0), 4 (L4) and 14 (L14) after initiation of adalimumab treatment (Table 1).

### Gene array

Gene expression analysis on the Human Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA, USA) was performed on ten paired punch biopsies from psoriatic patients. A total of 100 ng RNA was labelled with the Ambion WT Expression Kit (Ambion, Carlsbad, CA, USA) according to the manufacturer’s instructions. Samples were hybridised overnight to the GeneChip and scanned using an Affymetrix GCS 3000 7G scanner.

### Data processing

All array data processing and analysis was done in R version 3.1.2 (2014-10-31).

Background correction and normalisation of the raw data and robust multiarray analysis (RMA) were conducted with the Affy package [27] in R language. The Limma package [28] in R language was then applied to analyse the changes in gene expression values, while taking paired samples into account (untreated nonlesional (NL), untreated lesional psoriatic skin (L0), 4 days after adalimumab treatment start (L4) and 14 days after adalimumab treatment start (L14)).

All DEGs were corrected for multiple testing by Benjamini-Hochberg adjustment. However, due to lack of differentially expressed DEGs reaching a level of significance in the untreated lesional versus day 4 contrast, we performed a selection by a cut-off on +/- 0.58-log fold change (logFC) (+/- 1.5 fold changes) irrespective of p-values for further analyses. Probe IDs were converted into gene symbols using the hugene10sttranscriptcluster.db package. The

### Table 1. Details on patients included in the study.

Paired punch biopsies from ten psoriasis patients were used. Gender, age and Psoriasis Area and Severity Index (PASI) score are given for each patient; mean age = 50.6 years, mean PASI = 21.15. Available biopsy samples (NL, L, Day 4 and Day 14) are indicated with •.

| ID  | Gender | Age | NL | L  | PASI | Day 4 | Day 14 |
|-----|--------|-----|----|----|------|-------|-------|
| A01 | m      | 65  | •  | •  | 19.5 | •     | •     |
| A02 | m      | 59  | •  | •  | 12.8 | •     | •     |
| A03 | m      | 56  | •  | •  | 38.6 | •     | •     |
| A04 | m      | 36  | •  | •  | 21   | •     | •     |
| A05 | m      | 51  | •  | •  | 19.8 | •     | •     |
| A06 | m      | 52  | •  | •  | 15.6 | •     | •     |
| A07 | m      | 35  | •  | •  | 20.3 | •     | •     |
| A08 | f      | 50  | •  | •  | 29.6 | •     | •     |
| A09 | f      | 51  | •  | •  | 20.8 | •     | •     |
| A10 | f      | 51  | •  | •  | 13.5 | •     | •     |

doi:10.1371/journal.pone.0167437.t001
Limma package [28] in R language was applied to quantitatively examine the statistical differences between samples in a Principal Component Analysis (PCA) plot.

To visualise overlap of DEGs between contrasts, we used the Vennerable package. The selected genes were analysed, and a GSEA was performed in each contrast L0 versus NL, L0 versus L4 and L0 versus L14 using the Functional Annotation Tools from DAVID Bioinformatics Resources [24, 25].

Finally, the one pathway that was significantly enriched (p-value ≤ 0.05) by the selected genes was visualised by use of the Pathview package on KEGG pathway graphs (http://www.genome.jp/kegg/) [26].

Results

No genes were significantly regulated when comparing lesional psoriatic skin at day 0 and day 4 after adalimumab treatment initiation

RNA from samples collected from psoriasis patients on days 0 and 4 (n = 10) and on day 14 (n = 7) after adalimumab treatment initiation was analysed using the Affymetrix microarray. We found that 1,610 genes were differentially expressed between NL and L0 when using a +/- 0.58 logFC cut-off. Among the selected genes, 1,598 genes were significantly (adj. p-value < 0.05) differentially expressed in L0 versus NL contrast. Eight genes (none significant) were differentially expressed in L0 versus L4 contrast; 129 genes (9 significantly; adj. p-value < 0.05) were differentially expressed in the L0 versus L14 contrast; and 75 (none significant) genes were differentially expressed in the L4 versus L14 contrast (Fig 1). An overwhelming majority of the genes that

![Venn diagram indicating the overlap between differentially expressed genes in each contrast. Blue: lesional untreated versus lesional day 4. Purple: lesional day 4 versus lesional day 14. Green: Lesional untreated versus nonlesional untreated.](http://www.genome.jp/kegg/)
were differentially expressed in the L0 versus L4, L0 versus L14, and L4 versus L14 contrasts were also found in the L0 versus NL contrast. This prompted us to examine these overlapping DEGs more closely.

After adalimumab treatment, the relative gene expression in lesional psoriatic skin changes towards the relative gene expression in nonlesional psoriatic skin

A PCA plot showed differences between NL and L0 samples. The L0 and L4 samples appeared similar while L14 samples showed a tendency to approach the expression pattern of NL samples (Fig 2).

We plotted the relative expression of the selected genes, separating genes that were upregulated from those that were downregulated in L0 (Fig 3). Both up- and downregulated genes changed their expression towards the expression seen in nonlesional psoriatic skin. We analysed the genes for enriched gene ontology terms using the DAVID Functional Annotation Tools. The overlapping genes that were upregulated in L0 were enriched in cytokines. There

Fig 2. PCA plot of the samples (NL, L0, L4 and L14). The PCA plot shows clear differences between nonlesional skin (NL) and lesional untreated skin (L0). Also lesional skin 14 days after adalimumab treatment initiation (L14) tends to resemble the NL.

doi:10.1371/journal.pone.0167437.g002
were no significantly enriched terms for the overlapping genes downregulated in L0, although epidermis development was the least non-significant term.

The KEGG pathway: “Cytokine-cytokine receptor interaction; hsa04060” was significantly enriched after 4 and 14 days

Because no genes were significantly differentially expressed at day 4 after adalimumab treatment initiation, we performed a GSEA of all genes regulated more than +/- 0.58 log FC from each contrast by the David Functional Annotation Tools. We corrected for multiple testing and found four KEGG pathways that were significantly enriched by the genes from the list of 1,610 +/- 0.58 log FC genes (S1 Table) when untreated lesional and nonlesional psoriatic skin was compared. One KEGG pathway, the cytokine-cytokine receptor interaction (hsa04060), was significantly enriched in the genes from the list of eight annotated +/- 0.58 log FC genes when L0 and L4 were compared (adj. p-value = 4.02E-05). It was also significantly enriched in the genes from the list of 129 annotated, +/- 0.58 log fold changed genes (S2 Table) (adj. p-value = 8.90E-03) when comparing L0 with L14. Analysis of the genes involved in the cytokine-cytokine receptor interaction pathway and comparison of untreated lesional with nonlesional psoriatic skin showed that all genes involved were significantly differentially expressed in this contrast as well (S3 Table).

The KEGG view of the cytokine-cytokine receptor interaction pathway revealed possible early events in the anti-inflammatory mechanism of anti-TNF

We generated a KEGG view of the most enriched pathway; the cytokine-cytokine receptor interaction pathway (Figs 4–7). The KEGG view makes it possible to follow the gene expression patterns in this pathway over time.
Looking at the regulation of chemokines in the cytokine-cytokine receptor interaction pathway it is clear that 25 chemokines (IL8, IL8RB, IL8RA, CXCR4, CCR1, CXCL1, CXCL2, CXCL9, CXCL10, CXCL11, CXCL13, CXCL16, CXL1, CX3CR1, CCL3, CCL5, CCL8, CCL18, CCL19, CCL20, CCL22, CCR1, CCR2, CCR4 and CCR7) were upregulated and 3 (XCR1, CCL13 and CCL28) were downregulated in L0 compared with NL (Fig 4A). After 4 days of treatment, only seven chemokines (IL8, CXCL9, CXCL11, CCL3, CCL18, CCL19 and CCL20) showed changes in expression level compared with untreated lesional psoriatic skin (Fig 4B). In Fig 4B, these changes are shown as upregulation in L0 relative to L4, to make them comparable with the plot of L0 vs NL in Fig 4A, but they actually reflect the overall downregulation in L4 relative to L0 following treatment with adalimumab. This will be the case also for the remaining examples of L0 vs L4 or L14, where a depicted upregulation in the figures (to make it comparable to L0 vs NL) is discussed as downregulation following the changes in L4 and L14, and vice versa. After 14 days of treatment, 18 chemokines (IL8, IL8RB, CXCR4, CCR1, CXCL1, CXCL2, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CCL3, CCL18, CCL19, CCL20 and...
CCL21 were downregulated and one chemokine (XCR1) was upregulated compared with the starting point; untreated lesional psoriatic skin (Fig 4C).

In the KEGG pathway maps, eight proteins normally classified as cytokines were classified as hematopoieins. The hematopoieins showed less regulation overall. Comparison of L0 with NL showed that 14 hematopoieins (IL6, IL12, IL23A, IL2RA, IL2RG, IL4R, IL12RB2, IL13RA1, IL17R, OSM, OSMR, CSF2RA, CSF2RB and CSF3R) were upregulated and 5 (IL11RA, IL12RB, LIFR, GHR and PRLR) were downregulated in untreated lesional psoriatic skin (Fig 5A). After 4 days of treatment, no significant changes in regulation were seen (Fig 5B); but after 14 days of treatment, the expression pattern of this protein family began to resemble the one seen when comparing L0 with NL. Five hematopoieins (IL4R, IL13RA1, IL17R, CSF3R and OSMR) were downregulated and 3 (IL11RA, LIFR and PRLR) were upregulated compared with untreated lesional psoriatic skin (Fig 5C).

Fig 6. Cytokine-cytokine receptor interaction for the PDGF family, Interferon family and IL-10 family. (a) Untreated lesional versus nonlesional, (b) Untreated lesional versus 4 days after adalimumab treatment was initiated and (c) Untreated lesional versus 14 days after adalimumab treatment was initiated. (Colours refer to the expression level; green is downregulated, red is upregulated in untreated lesional psoriatic skin, grey is not regulated and white is not included in our data set) (Please find list of gene names in S4 Table).

doi:10.1371/journal.pone.0167437.g006

Fig 7. Cytokine-cytokine receptor interaction for the TNF family, IL-17 family and IL-1 family. (a) Untreated lesional versus nonlesional, (b) Untreated lesional versus 4 days after adalimumab treatment was initiated and (c) Untreated lesional versus 14 days after adalimumab treatment was initiated. (Colours refer to the expression level; green is downregulated, red is upregulated in untreated lesional psoriatic skin, grey is not regulated and white is not included in our data set) (Please find list of gene names in S4 Table).

doi:10.1371/journal.pone.0167437.g007
The plateleterived growth factor (PDGF) protein family was mainly downregulated in L0 compared with NL. Ten PDGF proteins (PDGFA, PDGFB, PDGFC, PDGFRB, FLT1, MET, EGFR, CSF1, CSF1R and KIT) were downregulated and 2 (VEGFA and FLT3) were upregulated in L0 compared with NL (Fig 6A). No change in regulation was seen in this protein family after 4 days of treatment (Fig 6B); but after 14 days of treatment, EGFR was upregulated and VEGFA was downregulated compared with L0 (Fig 6C).

In the interferon family, two proteins (IFNAR2 and IFNGR1) were upregulated in L0 compared with NL (Fig 6A). No change in regulation was detected after 4 days of treatment (Fig 6B); but after 14 days, IFNGR1 was downregulated compared with L0 (Fig 6C).

In the IL10 protein family, IL19, IL20 and IL10RA were upregulated and IL20RB was downregulated in L0 compared with NL (Fig 6A). After 4 days of treatment, IL19 and IL20 were downregulated (Fig 6B); and after 14 days of treatment, IL19 and IL20 were downregulated and IL20RB was upregulated compared with L0 (Fig 6C).

In the TNF protein family, 9 proteins (TNFSF10, SF1B, SF7, SF9, SF10A, SF10B, SF12A, SF21 and TGBF1) were upregulated and 8 (SF19, SF25, XEDAR, TGBF2, TGBF2R, ACVR1B, ACVR2 and BMPR1A) were downregulated in L0 compared with NL (Fig 7A). Only SF9 was upregulated after 4 days of treatment (Fig 7B), whereas SF21 was downregulated and SF19 was upregulated after 14 days of treatment compared with L0 (Fig 7C).

IL17A was upregulated in L0 compared with NL (Fig 7A) and downregulated in lesional skin after 14 days of treatment compared with L0 (Fig 7C).

IL1α and IL1β were upregulated and IL18 was downregulated in L0 compared with NL (Fig 7A). After 4 days of treatment, IL1α and IL1β were downregulated (Fig 7B); and after 14 days, IL1α and IL1β were downregulated and IL18 was upregulated compared with L0 (Fig 7C).

**Discussion**

We analysed gene expression in skin from psoriasis patients at day 0, 4 and 14 after initiation of adalimumab treatment, using a Human Gene 1.0 ST Array. We found 1,598 genes showing significant changes in expression level after adjusting for multiple testing and using a +/- 0.58 logFC cut-off. No genes showed significant changes in regulation 4 days after treatment. This was expected because no histological changes were seen at that stage, and only a few genes have previously been described to be regulated that early [29]. However, when viewed overall, genes that are differentially expressed at day 14 clearly show a trend in the same direction as early as at day 4.

The gene expression data were further analysed using the Functional Annotation Tools from DAVID Bioinformatics Resources. Focusing on pathways enriched by genes showing changes in regulation after 4 and 14 days of adalimumab treatment, we found that the only significantly enriched pathway after treatment was that of cytokine-cytokine receptor interaction. This is in line with earlier findings demonstrating that cytokines are regulated early after adalimumab treatment [29].

We generated a KEGG view of this pathway and this provided a more biologically relevant view on gene expression analysis than the one obtained with analysis of individual genes. The direction of gene regulation in pathways does not need to be the same for all involved genes as signalling pathways will frequently show reciprocal gene regulation [30, 31]. Several examples of this were seen in our data.

The KEGG view of the cytokine-cytokine receptor interaction showed how the signalling pathway changed over time and highlighted genes that may change early after treatment. After 4 days of adalimumab treatment, 11 cytokines were downregulated and one was upregulated compared with untreated lesional psoriatic skin; i.e., their regulatory pattern was
moving closer to that of nonlesional skin. IL-8 was initially upregulated in untreated lesional skin, but then downregulated in lesional skin after 4 days of treatment compared with untreated lesional skin. This is in line with earlier findings that TNFα regulates IL-8 [32]. In an ex vivo study of peripheral blood mononuclear cells, anti-TNF-α therapy has been observed to decrease the production of IL-8 [33]. Levels of serum IL-8 have been shown to be significantly decreased in rheumatoid arthritis (RA) patients on anti-TNF-a therapy [34] and reduced IL-8 production may reflect a significant amelioration in the inflammatory state of RA patients [35]. Furthermore, IL-8 is a keratinocyte-released chemokine known to attract neutrophils and T-cells [32, 36] suggesting a role in the immune response in the skin.

CXCL9 and CXCL11 were upregulated in untreated lesional psoriatic skin compared with nonlesional skin, and downregulated after 4 days of treatment compared with untreated lesional psoriatic skin. These proteins are CXCR3 ligands described to attract Th1/Th17-transient cells [37]. Interestingly, cytokines synthesized by Th17 cells stimulate keratinocytes and may be one of the most important drivers of the IL-23/Th-17 axis, which is important in driving keratinocyte hyperproliferation in psoriasis [38, 39]. The early downregulation of the two ligands after treatment suggests that TNF-α inhibition also inhibits Th1/Th17 cells through the CXCL9/CXCL11-CXCR-3 pathway.

CCL19 and CCL20 were upregulated in untreated lesional psoriatic skin, but downregulated after 4 days of treatment. The expression of CCL19 and its receptor CCR7 by central memory/naïve T cells and maturing dendritic cells has previously been described to be key event in the migration of these cells to the lymph nodes. The presence of lymphoid-like tissue has been observed in the dermis of psoriatic skin notes and have previously been described as important in the early event of decreasing inflammation in response to TNF-α inhibition [10, 11]. Bosè et al., (2013) analysed nine psoriasis patients after TNF-α inhibition and correlated gene expression fold change in lesional skin with the Psoriasis Area and Severity Index score decrease induced by TNF blockade after 4 weeks of treatment. After 4 weeks they showed that genes that were mostly associated with the clinical amelioration were CCR7, its ligand, CCL19, and dendritic cell maturation genes suggesting that inhibition of the CCR7/ CCL19 axis is a critical event for the clinical remission of psoriasis in response to TNF-α inhibition [10]. Goldminz et al., (2015) compared mRNA expression after two weeks of adalimumab treatment in nine patients (all responders) with mRNA expression in 12 methotrexate treated patients (all responders) [11]. They showed CCL20 downregulation after two weeks of adalimumab treatment and after 16 weeks of methotrexate treatment [11]. The fact that we found regulation of the same genes suggest that the effect of anti-TNF-α may be initiated as early as four days after treatment start.

The CCL3, IL19 and IL20 genes have been described to be upregulated in untreated lesional psoriatic skin, [40–42] and they were downregulated 4 days after adalimumab treatment start. Finally, IL1α and IL1β were downregulated after 4 days of adalimumab treatment start. IL-1β and IL-23 are required for IL-17A production in dermal T cells [43].

These results suggest that anti-TNF-α treatment works on a number of genes in the very early phase after treatment.

After 14 days of adalimumab treatment, the number of regulated chemokines had increased substantially. From the Pathview maps, it was observed that the regulation was changing towards the pattern in nonlesional psoriatic skin. This observation confirms that treated skin started to resemble nonlesional psoriatic skin after 14 days of adalimumab treatment. Interestingly, receptors like IL8RB and CCR1 showed downregulation after 14 days. The ligands of these receptors were downregulated after 4 days, which suggests that ligand downregulation may in some situations entail downregulation of their receptors as well.
Overall, these results suggest that one of the early events in the skin of psoriasis patients after adalimumab treatment is decreased attraction of immune cells by first downregulation of chemokines and then their receptors (e.g. *IL8* after 4 days and *IL8RB* after 14 days). Another early event is downregulation of genes involved in angiogenesis, e.g. *CCL19* and *CCL20* [44] at day 4 after treatment start and *VEGFA* [45] after 14 days.

The decrease in VEGF expression is further supported by another study of the effect of anti-TNF-α treatment in RA patients [46]. One week after patients received anti-TNF-α a decrease in VEGF serum concentration was observed and after two weeks, the concentration was returned to pre-treatment levels. These results correlated with decrease in disease severity [46].

After 14 days of adalimumab treatment, we observed regulation of cytokines involved in keratinocyte proliferation like *IL13RA1* [47] and *CXCR4* [48]. This is in line with histological changes observed, i.e. a decrease in epidermal thickness. [49] Furthermore, chemokines that are suggested to regulate the Th17 cell population were downregulated (*CXCL1* [50, 51] and *IL17A* [52]). This supports earlier studies showing that TNF-α inhibition in psoriasis is associated with a substantial Th17 cell-count reduction in the patients’ peripheral blood and that this decrease is significantly associated with an adequate response to biologic therapy [53].

Taken together, our pathway analysis provided a new overview of early biological events in psoriasis after adalimumab treatment. It should be emphasised that only patients undergoing adalimumab treatment have been included in this analysis. Therefore, we cannot tell if the biological events after remission are owing to adalimumab treatment or events seen in general after remission.

The pathway analysis tool is useful for classifying the continually increasing literature that explores the molecular mechanisms of the pathogenesis of psoriasis and remission after treatment. Many *in vitro* experiments have revealed local mechanistic events in simple models containing few cell types or few tissue types, but these experiments may not reflect the real-life biological changes as the interplay between different cell types and tissues is lacking in these models. The pathway analysis tool used in the present paper and its combination with microarray analysis on biopsies from psoriasis patients is a way of integrating earlier *in vitro* findings in the analysis and employing these findings when investigating the mechanisms that are involved *in vivo*. The inclusion of samples taken very early after anti-TNF-α treatment may add further knowledge to the effect of anti-TNF-α treatment. It can be discussed whether the effects seen after histological and clinical changes start appearing, is a primary effect of anti-TNF-α treatment or a secondary effect because of healing of the skin. Our results may better predict the primary effects of anti-TNF-α treatment as no histological of clinical changes in the skin are to be found this early.

Few have investigated gene expression in lesional psoriatic skin as early as four days after treatment start. This is probably due to the fact that it is very difficult to discover events this early as no histological or clinical changes appears and the differences in the gene expression may be very small.

Few have investigated gene expression in lesional psoriatic skin as early as four days after treatment start. It is difficult to discover events this early as no histological or clinical changes has appeared and the differences in the gene expression may be very small.

The approach of integrating the GSEA made us discover possible expression changes four days after treatment start. A number of these changes have been shown in other studies of anti-TNF-α treatment after histological and clinical changes start appearing. Our result suggest that these changes in gene expression may appear as early as four days after treatment start and earlier than the histological and clinical changes start appearing.
Supporting Information

S1 Table. 1,610 +/- 0.58 log FC genes in the comparison of untreated lesional and nonlesional psoriatic skin. Gene expression analysis on the Human Gene 1.0 ST Array was performed on ten paired punch biopsies from psoriatic patients. Data processing and analysis was done in R version 3.1.2 (2014-10-31). Background correction and normalisation of the RMA were conducted with the Affy package and gene expression analysis was conducted with the Limma package. Probe IDs were converted into gene symbols using the hugene10sttranscriptcluster.db package. All DEGs were corrected for multiple testing by Benjamini-Hochberg adjustment and a selection by a cut-off on +/- 0.58-log fold change (logFC) (+/- 1.5 fold changes) irrespective of p-values was performed. Blue: significantly downregulated in lesional psoriatic skin compared with nonlesional psoriatic skin. Red: significantly upregulated in lesional psoriatic skin compared with nonlesional skin. Black: nonsignificantly +/- 0.58 log FC genes.
(XLSX)

S2 Table. +/- 0.58 log FC genes in the comparison of lesional psoriatic skin and psoriatic skin 4 days after adalimumab treatment and in the comparison of lesional psoriatic skin and psoriatic skin 14 days after adalimumab treatment. Gene expression analysis on the Human Gene 1.0 ST Array was performed on ten paired punch biopsies from psoriatic patients. Data processing and analysis was done in R version 3.1.2 (2014-10-31). Background correction and normalisation of the RMA were conducted with the Affy package and gene expression analysis was conducted with the Limma package. Probe IDs were converted into gene symbols using the hugene10sttranscriptcluster.db package. All DEGs were corrected for multiple testing by Benjamini-Hochberg adjustment and a selection by a cut-off on +/- 0.58-log fold change (logFC) (+/- 1.5 fold changes) irrespective of p-values was performed. 8 genes +/- 0.58 log FC regulated between lesional psoriatic skin and at day 4 after adalimumab treatment. 129 genes +/- 0.58 log FC regulated between lesional psoriatic skin and at day 14 after adalimumab treatment. Blue: significantly downregulated in lesional psoriatic skin compared with 14 days after adalimumab treatment. Red: significantly upregulated in lesional psoriatic skin compared with 14 days after adalimumab treatment. Black: nonsignificantly +/- 0.58 log FC genes.
(XLSX)

S3 Table. Genes involved in Cytokine-cytokine receptor pathway. Gene expression analysis on the Human Gene 1.0 ST Array was performed on ten paired punch biopsies from psoriatic patients. Data processing and analysis was done in R version 3.1.2 (2014-10-31). Background correction and normalisation of the RMA were conducted with the Affy package and gene expression analysis was conducted with the Limma package. Probe IDs were converted into gene symbols using the hugene10sttranscriptcluster.db package. All DEGs were corrected for multiple testing by Benjamini-Hochberg adjustment and a selection by a cut-off on +/- 0.58-log fold change (logFC) (+/- 1.5 fold changes) irrespective of p-values was performed. 10 significantly upregulated genes in lesional psoriatic skin compared with 14 days genes—all involved in the Cytokine-cytokine receptor pathway.
(XLSX)

S4 Table. List of gene names. Gene expression analysis on the Human Gene 1.0 ST Array was performed on ten paired punch biopsies from psoriatic patients. Probe IDs were converted into gene symbols using the hugene10sttranscriptcluster.db package.
(XLSX)
Author Contributions

Conceptualization: AL LCO PS FD LR CJ LI.
Data curation: AL LCO PS FD SB.
Formal analysis: AL LCO PS FD SB.
Funding acquisition: AL LR LI.
Investigation: AL LCO PS FD LR CJ LI.
Methodology: AL LCO PS FD SB.
Project administration: AL PS FD CJ LI.
Resources: AL LCO PS FD CJ LI.
Software: AL LCO PS FD SB.
Supervision: PS FD CJ LI.
Validation: AL LCO PS FD.
Visualization: AL LCO.
Writing – original draft: AL.
Writing – review & editing: AL LCO PS FD LI.

References

1. Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, et al. Steroidogenesis in the skin: implications for local immune functions. The Journal of steroid biochemistry and molecular biology. 2013; 137:107–23. doi: 10.1016/j.jsbmb.2013.02.006 PMID: 23435015
2. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: Regulation of local and global homeostasis by the skin neuroendocrine system. Advances in anatomy, embryology, and cell biology. 2012; 212:v-115.
3. Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharis TC, Rivier J. Key Role of CRF in the Skin Stress Response System. Endocrine reviews. 2013; 34(6):827–84. doi: 10.1210/er.2012-1092 PMID: 23939821
4. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001; 15(1):16–7. Epub 2001/07/14. PMID: 11451313
5. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007; 445 (7130):866–73. Epub 2007/02/23. doi: nature05663 [pii] doi: 10.1038/nature05663 PMID: 17314973
6. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361(5):496–509. Epub 2009/07/31. doi: 361/5/496 [pii] doi: 10.1056/NEJMr0804595 PMID: 19641206
7. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003; 13(1):69–78. Epub 2003/03/20. 13/1/69 [pii]. doi: 10.1152/physiolgenomics.00157.2002 PMID: 12644634
8. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques. The Journal of Immunology. 2005; 175(4):2721–9. PMID: 16081850
9. Zaba LC, Cardinale I, Gillieaudoue P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007; 204(13):3183–94. PubMed Central PMCID: PMCPMC2150965. doi: 10.1084/jem.20071094 PMID: 18039949
10. Bose F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A, et al. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis. Am J Pathol. 2013; 183(2):413–21. Epub 2013/06/05. doi: 10.1016/j.ajpath.2013.04.021 PMID: 23731727
Kalden JR, Nusslein HG, Wollenhaupt J, Burmester GR, Kruger K, Antoni C. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clinical and experimental rheumatology. 2008; 26(5):834–40. PMID: 19032816

Miele E, Markowitz JE, Mamarla P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. Journal of pediatric gastroenterology and nutrition. 2004; 38(5):502–8. Epub 2004/04/21. PMID: 15097438

Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla A, Peiteado D, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthitis with infliximab. Ann Rheum Dis. 2012; 71(12):1955–60. Epub 2012/05/09. doi: 10.1136/annrheumdis-2011-200826 PMID: 22563028

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014; 53(2):213–22. Epub 2013/08/16. PubMed Central PMCID: PMCPmc3894670.

Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNFalpha therapy in psoriatic arthritis. Rheumatology (Oxford). 2005; 44(3):390–7. Epub 2005/02/08.

Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004; 279(31):32633–42. Epub 2004/05/18. doi: 10.1074/jbc.M400642200 PMID: 15145954

Zhou A, Scoogg S, Gaynor RB, Williams NS. Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene. 2003, 22(13):2054–64. Epub 2003/04/04. doi: 10.1038/sj.onc.1206262 PMID: 12673210

Feldmann M, Maini RM. ANTI-TNFalpha THERAPY OF RHEUMATOID ARTHRITIS: What Have We Learned? Annu Rev Immunol. 2001; 19:163–96. doi: 10.1146/annurev.immunol.19.1.163 PMID: 11244034

Katou F, Ohtani H, Nakayama T, Nagura H, Yoshie O, Motegi K. Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin. J Pathol. 2003; 199(1):98–106. doi: 10.1002/path.1255 PMID: 12472322

Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 2008; 9(4):378–87. doi: 10.1038/nri1576 PMID: 18345002

Zaba LC, Suárez-Farías M, Fuentes-Duculan J, Nograles KE, Guttmann-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. Journal of Allergy and Clinical Immunology. 2009; 124(5):1022–30.e395. doi: 10.1016/j.jaci.2009.08.046 PMID: 19895991

Bose F, Raeli L, Garuti C, Frigerio E, Cozzi A, Crimi M, et al. Dual role of anti-TNF therapy: Enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clinical Immunology. 2011; 139(2):164–76. doi: 10.1016/j.clim.2011.01.015 PMID: 21334981

Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44–57. Epub 2009/01/10. doi: 10.1038/nprot.2008.211 PMID: 19131956

Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1–13. Epub 2008/11/27. PubMed Central PMCID: PMCPmc2615629. doi: 10.1093/nar/gkn923 PMID: 19033363

Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013; 29(14):1830–1. PubMed Central PMCID: PMCPmc3702256. doi: 10.1093/bioinformatics/btt285 PMID: 23740750

Gautier L, Cope L, Bolstad BM, Irizarry RA. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307–15. Epub 2004/02/13. doi: 10.1093/bioinformatics/btg405 PMID: 14960456

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies affy—analysis of Affymetrix GeneChip data at the probe level. (1362–4962 (Electronic)). doi: D—NLM: PMC4402510 EDAT—2015/01/22 06:00 MHDA-2015/07/09 06:00 CRDT—2015/01/22 06:00 PHST—2015/01/06 [accepted] PHST—2014/11/09 [received] PHST—2015/01/20 [aheadofprint] AID—gkv007 [pii] AID—10.1093/nar/gkv007 [doi] PSTD—ppublish.

Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L, et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic
skin by anti-TNFα therapy. British Journal of Dermatology. 2010; 163(6):1194–204. doi: 10.1111/j.1365-2133.2010.10036.x PMID: 20846304

30. Kemp DM, Nirmala NR, Szustakowski JD. Extending the pathway analysis framework with a test for transcriptional variance implicates novel pathway modulation during myogenic differentiation. Bioinformatics. 2007; 23(11):1356–62. Epub 2007/03/30. doi: 10.1093/bioinformatics/btm116 PMID: 17392237

31. Saxena V, Orgill D, Kohane I. Absolute enrichment: gene set enrichment analysis for homeostatic systems. Nucleic Acids Res. 2006; 34(22):e151. Epub 2006/11/30. PubMed Central PMCID: PMCPmc1702493. doi: 10.1093/nar/gkl766 PMID: 17130162

32. Wolfe U, Haarhaus B, Schempp CM. Amorogentin Displays Immunomodulatory Effects in Human Mast Cells and Keratinocytes. Mediators Inflamm. 2015; 2015:630128. Epub 2015/11/26. PubMed Central PMCID: PMCPmc4639662. doi: 10.1155/2015/630128 PMID: 2660671

33. Lun SWM, Wong CK, Tam LS, Li EK, Lam CWK. Decreased ex vivo production of TNF-α and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. International Immunopharmacology. 2007; 7(13):1668–77. doi: 10.1016/j.intimp.2007.08.021 PMID: 17996676

34. Klimiuk PA, Sierakowski S, Dormyslawska I, Chewiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis Clinical and experimental rheumatology. 2006; 25:529–33.

35. Dominical VM, Bertolo MB, Almeida CB, Garrido VT, Miguel LI, Costa FF, et al. Neutrophils of Rheumatoid Arthritis Patients on Anti-TNF-α Therapy and in Disease Remission Present Reduced Adhesive Functions in Association with Decreased Circulating Neutrophil-Attractant Chemokine Levels. Scandinavian Journal of Immunology. 2011; 73(4):309–18. doi: 10.1111/j.1365-3083.2011.02503.x PMID: 21208248

36. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science. 1989; 243(4897):1464–6. Epub 1989/03/17. PMID: 2648569

37. Witte E, Kokolakis G, Witte K, Warszawska K, Friedrich M, Christou D, et al. Interleukin-29 induces epithelial production of CXCR3A ligands and T-cell infiltration. J Mol Med (Berl). 2015. Epub 2015/11/28.

38. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129(6):1339–50. Epub 2009/03/27. doi: 10.1038/jid.2009.59 PMID: 19322214

39. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of Psoriasis: Recent Advances on IL-23 and Th17 Cytokines. Current rheumatology reports. 2007; 9(6):461–7. PMID: 18177599

40. Chen L, Wu J, Pier E, Zhao Y, Shen Z. mTORC2-PKBalpha/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis. J Invest Dermatol. 2013; 133(2):418–28. Epub 2012/12/12. doi: 10.1038/jid.2012.333 PMID: 23223135

41. Keemann M, Koks S, Reimann E, Prans E, Abram K, Kingo K. Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. BMC Genomics. 2015; 16:322. Epub 2015/04/22. PubMed Central PMCID: PMCPmc4405864. doi: 10.1186/s12864-015-1508-2 PMID: 25897967

42. Otkjær K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005; 153(5):911–8. Epub 2005/10/18. doi: 10.1111/j.1365-2133.2005.06800.x PMID: 16225599

43. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011; 35(4):596–610. PubMed Central PMCID: PMCPMC3205267. doi: 10.1016/j.immuni.2011.08.001 PMID: 21982596

44. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Mandelin AM 2nd, Shaharara S. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum. 2011; 63(4):914–22. Epub 2011/01/13. PubMed Central PMCID: PMCPmc3079365. doi: 10.1002/art.30323 PMID: 21225692

45. Marina ME, Roman II, Constantin AM, Mihu CM, Tataru AD. VEGF involvement in psoriasis. Clujul medical (1957). 2015; 88(3):247–52. Epub 2015/11/27. PubMed Central PMCID: PMCPmc4639662. doi: 10.1155/2015/630128 PMID: 2660671

46. Paleolog EM, Young S, Stark AC, McCloskey R, Feldmann M, Maini RN. Modulation of Angiogenic Vascular Endothelial Growth Factor by Tumor Necrosis Factor alpha and Interleukin-1 in Rheumatoid Arthritis. Arthritis & Rheumatism. 1998; 41(7):1258–65.

47. Wongpiyabovorn J, Suto H, Ushio H, Izuhara K, Mitsuishi K, Ikeda S, et al. Up-regulation of interleukin-1 receptor alpha 1 on human keratinocytes in the skin of psoriasis and atopic dermatitis. J Dermatol Sci. 2003; 33(1):31–40. Epub 2003/10/07. PMID: 14527737

48. Takekoshi T, Wu X, Mitsu H, Tada Y, Kao MC, Sato S, et al. CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis. J Invest Dermatol. 2013; 133(11):2530–7. Epub 2013/03/27. PubMed Central PMCID: PMCPmc3972890. doi: 10.1038/jid.2013.151 PMID: 23528817

49. Soegaard-Madsen L, Johansen C, Iversen L, Kragballe K. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. Br J
50. Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015; 24(7):529–35. Epub 2015/04/02. doi: 10.1111/exd.12710 PMID: 25828362

51. Campanati A, Orciani M, Consales V, Lazzarini R, Ganzetti G, Di Benedetto G, et al. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Arch Dermatol Res. 2014; 306(10):915–20. Epub 2014/08/28. doi: 10.1007/s00403-014-1493-3 PMID: 25160906

52. El Malki K, Karbach SH, Huppert J, Zayoud M, Reissig S, Schuler R, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol. 2013; 133(2):441–51. Epub 2012/09/07. doi: 10.1038/jid.2012.318 PMID: 22951726

53. Piaserico S, Sandini E, Saldan A, Abate D. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis. Drug development research. 2014; 75 Suppl 1:S73–6. Epub 2014/11/11.